what are the glp-1 agonists Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review GLP-1 Receptor Agonists and Research

The Gut Microbial Endocrine Organ: Bacterially Derived Signals Driving Cardiometabolic Diseases (book chapter, review)

Trial registration Similar content being viewed by others Introduction Metabolic syndrome (MetS) is defined as a cluster of cardiovascular risk factors (i.e., abdominal obesity, hyperinsulinaemia, atherogenic dyslipidemia, hypertension, hypercogauability) that increase the risk of developing co-existing coronary heart disease (CHD) and type 2 diabetes [1]

H., MacIsaac, R

The E75 (nelipepimut-S) vaccine showed promising efficacy in stimulating an in vivo immune response and might reduce the disease recurrence rate in disease-free, node-positive, and high-risk node-negative breast cancer patients

In preclinical models, both peptides have been shown to enhance the formation of new capillaries, improving nutrient and oxygen delivery to damaged tissue